Specifications Manual for Joint Commission National Quality Measures (v2020B2)
Posted: 9/2/2020
Home » Appropriate Justification for Multiple Antipsychotic Medications

Release Notes:
Data Element
Version 2020B2

Name:Appropriate Justification for Multiple Antipsychotic Medications
Collected For: HBIPS-5
Definition:Documentation in the medical record of appropriate justification for discharging the patient on two or more routine antipsychotic medications.
Question:Is there documentation in the medical record of appropriate justification for the patient being discharged on two or more antipsychotic medications?
Format:
Length:1
Type:Alphanumeric
Occurs:1
Allowable Values:

1    The medical record contains documentation of a history of a minimum of three failed multiple trials of monotherapy.

2    The medical record contains documentation of a recommended plan to taper to monotherapy due to previous use of multiple antipsychotic medications OR documentation of a cross-taper in progress at the time of discharge.

3    The medical record contains documentation of augmentation of Clozapine.

4    The medical record contains documentation of a justification other than those listed in Allowable Values 1-3.

5    The medical record does not contain documentation supporting the reason for being discharged on two or more antipsychotic medications OR unable to determine from medical record documentation.
Notes for Abstraction:If the patient was in an acute-care hospital and had multiple admissions to the psychiatric unit during his or her hospitalization, this information should be abstracted only once at the time of discharge from the hospital or at the time of final discharge from the psychiatric unit.

"Failed multiple trials of monotherapy" comprises a history of three or more failed trials of monotherapy in which there was a lack of sufficient improvement in symptoms or functioning.
  • The trials could have been conducted with three different medications in which the documentation must include at a minimum the names of the antipsychotic medications that previously failed.
OR
  • There could have been multiple trials with the same medication but different doses and timing of administration, in which case the documentation should include the names of the medication and a statement that the trials failed with different dosing and/or timing.

A cross-taper plan is defined as a plan to decrease the dosage of one or more antipsychotic medications while increasing the dosage of another antipsychotic medication to a level which results in controlling the patient's symptoms with one antipsychotic medication.

Both the recommended plan to taper to monotherapy and the cross-taper plan must include the name(s) of the medication(s) to be tapered.

Only allowable values 1, 2 and 3 are supported by an evidence base which will allow the case to pass the measure. Allowable value 4 can be used as part of an internal performance improvement activity, but the case will not pass the measure.
Suggested Data Sources:
  • Aftercare discharge plan
  • Discharge plan
  • Final discharge summary
  • History and physical
  • Interim discharge summary
  • Medication reconciliation form
  • Physician discharge orders
  • Physician progress notes
  • Referral form
Additional Notes:

Guidelines for Abstraction:
Inclusion Exclusion
  • None
  • None

Appropriate Justification for Multiple Antipsychotic Medications
CPT® only copyright 2019 American Medical Association. All rights reserved.
Specifications Manual for Joint Commission National Quality Measures (v2020B2)
Discharges 07-01-20 (3Q20) through 12-31-20 (4Q20)

LICENSE FOR USE OF CURRENT PROCEDURAL TERMINOLOGY, FOURTH EDITION (“CPT®”)

CPT® only copyright 2019 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

You, your employees and agents are authorized to use CPT® only as contained in The Joint Commission performance measures solely for your own personal use in directly participating in healthcare programs administered by The Joint Commission. You acknowledge that the American Medical Association (“AMA”) holds all copyright, trademark and other rights in CPT®.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT® for resale and/or license, transferring copies of CPT® to any party not bound by this Agreement, creating any modified or derivative work of CPT®, or making any commercial use of CPT®. License to use CPT® for any use not authorized herein must be obtained through the American Medical Association, Intellectual Property Services, AMA Plaza, 330 North Wabash Avenue, Suite 39300, Chicago, Illinois 60611-5885. Applications are available at the American Medical Association Web site, www.ama- assn.org/go/cpt.

U.S. Government Rights This product includes CPT® which is commercial technical data, which was developed exclusively at private expense by the American Medical Association, 330 North Wabash Avenue, Chicago, Illinois 60611. The American Medical Association does not agree to license CPT® to the Federal Government based on the license in FAR 52.227-14 (Data Rights - General) and DFARS 252.227-7015 (Technical Data - Commercial Items) or any other license provision. The American Medical Association reserves all rights to approve any license with any Federal agency.

Disclaimer of Warranties and Liabilities. CPT® is provided “as is” without warranty of any kind, either expressed or implied, including but not limited to the implied warranties of merchantability and fitness for a particular purpose. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT®, and the (AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this product is with The Joint Commission, and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this product.

This Agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this Agreement.

Should the foregoing terms and conditions be acceptable to you, please indicate your agreement and acceptance by clicking below on the button labeled “accept”.

^